Business
Collaboration in sports-related concussions
Collaboration in sports-related concussions.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 1237D Oxford BioDynamics PLC 29 January 2018 \n\n29 January 2018\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford BioDynamics signs collaboration agreement with Holos to develop biomarkers for sports-related concussions\n \nOxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces that it has entered into a collaboration with Holos Life Sciences Pte. Ltd (\"Holos\") to develop non-invasive epigenetic biomarkers associated with sports-related concussions.\n \nThe collaboration will leverage OBD's EpiSwitch™ platform to help determine and monitor systemic epigenetic changes and potential physiological reprogramming due to sports-related concussion. Based on pre- and post-concussion monitoring, biomarkers will be identified and evaluated to assist in the determination of changes in an individual's epigenetic profiles, in response to a concussive event. EpiSwitch™ stratification will provide new insights and help to quantify the risk of prolonged effects of sports-related concussion, and potentially improve recovery and rehabilitation.\n \nUnder the terms of the collaboration agreement, Holos will supply the participants' blood samples, with OBD providing its proprietary EpiSwitch™ platform and methodology for the development, evaluation, and validation of epigenetic biomarkers. Biomarker readouts will be based on minimally invasive blood testing.\n \nThe analysis aims to identify a signature of EpiSwitch™ biomarkers to evaluate the impact of sports-related concussive events on individuals. Informative EpiSwitch™ biomarkers potentially could be monitored in relation to concussive events to inform return-to-play protocols and determine when athletes can resume activities.\n \nChristian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:\n \n\"We are delighted to be working with Holos on a new front for the EpiSwitch™ biomarker platform. Based on our previous studies and stratification results, we believe that we can make an important contribution to the analysis of sport-related concussions, help im...